The pharmaceutical sterility testing market be made up of sales of pharmaceutical sterility testing products and interrelated services which are castoff to confirm that pharmaceutical products are free from the attendance of the viable microorganisms. Pharmaceutical sterility tests are processes for checking the occurrence of microorganism in biological parenteral which are proposed for human usage. Pharmaceutical sterility testing is an imperative process in pharmaceuticals, medical equipment, and drugs manufacturing to calculate the effectiveness of a sterilization procedure and is carried out at all levels of manufacturing to diminish the risk of product contamination.
According to the report analysis, ‘Pharmaceutical Sterility Testing Global Market Report 2020-30: Covid 19 Impact and Recovery’ states that the worldwide pharmaceutical sterility testing market is probable to deduct from USD 1.02 billion in 2019 to USD 1 billion during 2020 at a compound annual growth rate (CAGR) of -3%. While the entire sterility testing market is a deduction in 2020 owing to COVID-19, some market segments (medical devices and drugs used for covid19), will increase significantly. Stopping of pharmaceutical and medical devices introduction owing to COVID-19 has impacted the sterility testing market. The market is predicted to recover and reach USD 1.39 billion during 2023 at a CAGR of 8%.
Additionally, major players in the pharmaceutical sterility testing market are Pacific Biolabs, STRERIS Corporation, Boston Analytical, Gibraltar Laboratories, Sartorius AG, SolviasAG, SGS AG, Toxikon, Inc., Pace Analytical Services LLC and Charles River Laboratories International, Inc. Companies in the pharmaceutical testing market are establishing the new pharmaceutical sterility testing products and services to augment its product portfolio and enlarge its existence in the market. The corporates are launching technologically advanced products and well-equipped services to exploit growth potential of the increasing pharmaceutical sterility market. For instance, during 2019, RSSL launched a sterility testing service for pharmaceutical and medical device companies which offers reckless, responsive and flexible test services.
The RSSL’s new sterility testing service comprises two methods, membrane filtration for aqueous, alcohol, solvent and oil-based products and direct inoculation tests for non-soluble to regulate the existence of contaminating microorganisms in sterilized or aseptic drug products. Similarly, during December 2018, Merck, a leading sterility testing device producer, launched Steritest NEO Device, an opportune and effective sterility device utilized for pharmaceutical drug testing.
Augmented in the number of drug launches and growing the investment on research and development (R&D) underwritten to the growth of pharmaceutical sterility testing market. Sterility is an essential step in the production of drugs to avoid product contamination and generate the drugs free from any viable microorganism. According to a report circulated by International Federation of Pharmaceutical Manufacturers & Associations during 2017, nearly USD 149.8 billion was spent by worldwide pharmaceutical industry for R&D activities. Additionally, according to Pharma and Annual Review 2019 report, 1,273 fresh drugs were launched in the worldwide market in 2019, a 6.2% augment from the previous year. Augmented the emphasis in the quality and sterility coupled with growing R&D activities in pharmaceutical segment and rising production and launch of drug and medical devices is propelling the market.
For More Information, Click on the Link Below:-
Global Sterility Testing Market Research Report: Product Type (Instruments, Services), Test Type (Membrane Filtration, Direct Transfer) End-User (Pharmaceutical Companies, Hospitals & Clinics, Academic & Research Laboratories) – Global Forecast Till 2023
Ankur Gupta, Head Marketing & Communications